NewAmsterdam Pharma Company N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NAMS research report →
Range $45 – $61
Price Chart
About the company
NewAmsterdam Pharma Company N. V. , a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
- CEO
- Michael Harvey Davidson Facp.
- IPO
- 2021
- Employees
- 100
- HQ
- Naarden, NH, NL
Get TickerSpark's AI analysis on NAMS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.21B
- P/E
- -11.34
- Fwd P/E
- 16.13
- PEG
- -1.38
- P/S
- 89.66
- P/B
- 3.82
- EV/EBITDA
- -9.31
- Div Yield
- 0.00%
- Gross Margin
- 97.84%
- Op Margin
- -900.07%
- Net Margin
- -789.94%
- ROE
- -31.39%
- ROIC
- -37.01%
Latest fiscal year · YoY change
- Revenue
- $22.50M-50.6%
- Gross Profit
- $22.44M-50.7%
- Op Income
- $-225,683,000
- Net Income
- $-203,819,000+15.6%
- EPS
- $-1.75+31.6%
- OCF Growth
- +6.8%
- FCF Growth
- +7.0%
- 52W High
- $42.21
- 52W Low
- $17.90
- 50D MA
- $21.18
- 200D MA
- $28.90
- Beta
- 0.10
- RSI (14)
- 38
- Avg Volume
- 1.64M
No earnings-call transcripts are available for NAMS yet.
- Free Float
- 68.3%
- Shares Outstanding
- 119.93M
- Float Shares
- 81.89M
of shares held by institutions
213 13F filers
Buy/sell ratio 0.70. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 18.09M | ▲ 1.15M |
| Capital World Investors | 12.88M | ▲ 650.93K |
| Fmr LLC | 12.12M | ▲ 1.78M |
| Ra Capital Management, L.P. | 9.55M | 0 |
| Fcpm Iii Services B.V. | 8.49M | ▼ 708.55K |
| Deerfield Management Company, L.P. | 4.26M | 0 |
| Viking Global Investors LP | 4.20M | 0 |
| Bain Capital Life Sciences Investors, LLC | 3.81M | ▼ 3.50M |
| Maverick Capital Ltd | 3.27M | ▲ 1.08M |
| Duquesne Family Office LLC | 3.07M | 0 |
| Jupiter Topco LLC | 2.54M | ▲ 2.54M |
| Janus Henderson Group Ltd. | 2.26M | ▼ 82.74K |
Held by 113 ETFs
Biggest fund positions in NAMS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | Kastelein Johannes Jacob Pieter | other | 50,246 |
| Sep 30, 26 | Kastelein Johannes Jacob Pieter | other | 50,246 |
| Sep 30, 26 | Kastelein Johannes Jacob Pieter | sell | 50,246 |
| Sep 14, 26 | Davidson Michael H. | buy | 10,000 |
| Sep 4, 26 | Smither John W | sell | 1,600 |
| Sep 1, 26 | Gunning Robert William | other | 14,000 |
| Sep 1, 26 | Gunning Robert William | other | 3,200 |
| Aug 24, 26 | Kastelein Johannes Jacob Pieter | other | 125,000 |
| Aug 24, 26 | Kastelein Johannes Jacob Pieter | other | 125,000 |
| Aug 24, 26 | Kastelein Johannes Jacob Pieter | sell | 125,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NAMS coverage
Recent articles, reports, and earnings notes.
No research on NAMS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NAMS report →NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 6
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 4
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
globenewswire.com · Nov 4
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November
globenewswire.com · Nov 3
NewAmsterdam Pharma (NASDAQ:NAMS) Hits New 1-Year Low – Should You Sell?
defenseworld.net · Oct 16
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Oct 2
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer's Disease
globenewswire.com · Sep 29
Menarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo® y Evlarco®
prnewswire.com · Sep 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.